Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 701–800 of 932
Mateos, M., Gustine, J. N., Puertas, B., & Raje, N. S. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00236 · Cited by 1
Koops, M., Bertamini, L., Papazian, N., Korst, C. L. B. M., Budai, M. J., Hoogenboezem, R. M., Sanders, M. A., van der Holt, B., van Duin, M., Broijl, A., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0080 · Cited by 1
Risk Stratification in Newly Diagnosed Smoldering Multiple Myeloma
Mateos, M., & Miguel, J. F. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_1 · Cited by 1
Energy Balance and Multiple Myeloma in African Americans
Colditz, G. A., Bohlke, K., Chang, S., & Carson, K. (2014) · Springer eBooks · doi:10.1007/978-3-319-06103-0_6 · Cited by 1
Marcadores pronósticos en pacientes con gammapatía monoclonal de significado incierto
Medina, S., Espiño, M., Blanchard, M. J., Alenda, R., Roldán, E., & Villar, L. M. (2013) · Inmunología · doi:10.1016/j.inmuno.2013.10.001 · Cited by 2
Tun, N. M., Joseph, G., Soe, A. M., & Ford, J. G. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1990-z · Cited by 1
Li, R., Du, J., & Hou, J. (2014) · Hematology · doi:10.1179/1607845414y.0000000163 · Cited by 1
Chemoprevention for smoldering multiple myeloma: not ready for prime time
Gertz, M. A. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.790545 · Cited by 1
Criteria for Diagnosis and Response
Kyle, R. A., & Rajkumar, S. V. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_1 · Cited by 1
Self-citationEtiologia i patogeneza szpiczaka plazmocytowego
Iskierka‐Jazdzewska, E., & Jamroziak, K. (2015) · Hematologia · doi:10.5603/hem.2015.0037 · Cited by 1
Diagnosis and Therapy for Multiple Myeloma: Practice Guidelines
Kurokawa, M. (2007) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.96.2312 · Cited by 1
Бессмельцев, С. С. (2013) · Clinical oncohematology · doi:10.21320/2500-2139-2013-6-4-379-414 · Cited by 7
Backache could be an indication of multiple myeloma: An unusual case report
Ullah, M. R., Kashif, M., Nadeem, A., Tahir, R., Rizwan, Z., Rizwan, N. U. N., & Afzal, N. (2018) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v17i2.35892 · Cited by 1
Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab
Janmaat, M. L., van de Donk, N. W. C. J., van Bueren, J. J. L., Ahmadi, T., Sasser, A. K., Jansson, R. K., Lokhorst, H. M., & Parren, P. W. H. I. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch7 · Cited by 2
Classification OMS 2017 des tumeurs plasmocytaires
Cornet, É. (2019) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(19)30223-0 · Cited by 1
Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma
Солодовник, А. А., Mkrtchian, A. S., Misyurin, V. A., Кесаева, Л. А., Касаткина, Н. Н., Votyakova, O. M., Юрьевна, Я. О., Medvedovskaya, E. G., Антипова, А. С., Заводнова, И. З., et al. (2019) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2019-18-1-50-59 · Cited by 1
Sørrig, R. (2020) · British Journal of Haematology · doi:10.1111/bjh.16598 · Cited by 1
“The overall risk of developing symptomatic multiple myeloma (MM) from the asymtomatic precursor state, smoldering multiple myeloma (SMM), is 10% per year, but varies greatly with the presence of certain risk factors.(1) The heterogeneous clinical course of SMM has led the International Myeloma Working Group (IMWG) to…”
Background[Advances in the diagnosis and treatment of multiple myeloma].
Huang, B., & Li, J. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.07.018 · Cited by 1
Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma
Abramson, H. N. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94196 · Cited by 1
Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment?
Callander, N. S. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.5043 · Cited by 1
Kunacheewa, C., & Manasanch, E. E. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1984225 · Cited by 1
Goldsmith, S. R., & Stockerl-Goldstein, K. E. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.01.009 · Cited by 1
Oben, B., Cosemans, C., Geerdens, E., Linsen, L., Vanhees, K., Maes, B., Theunissen, K., Cruys, B., Lionetti, M., Arijs, I., et al. (2022) · Cancers · doi:10.3390/cancers14041035 · Cited by 1
“Smoldering multiple myeloma (SMM) is a premalignant condition defined by a higher disease burden, with the annual risk for progression of 10% in the first five years, 3% per year for the next five years and finally 1% per year for the subsequent years [2].”
BackgroundAzees, P. A. A., Suganthy, N., Amaechi, B. T., Thajuddin, N., Raghavendra, V. B., Brindhadevi, K., Pugazhendhi, A., & Phuong, T. N. (2022) · Process Biochemistry · doi:10.1016/j.procbio.2022.04.013 · Cited by 1
The Path Forward in Multiple Myeloma: 2021 Jan Waldenstrom Award Lecture
Rajkumar, S. V. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.04.021 · Cited by 1
Self-citationBrunning, R. D., & Arber, D. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06969-4.00002-7 · Cited by 1
Fenton, D. S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-2904-5.00048-3 · Cited by 1
Barber, R. D., & Kroeger, K. (2022) · Healthcare delivery in the information age · doi:10.1007/978-3-030-95675-2_3 · Cited by 1
Recent developments on the application of molecular probes in multiple myeloma: Beyond [18F]FDG
Zhang, S., Shang, J., Ye, W., Zhao, T., Xu, H., Zeng, H., & Wang, L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.920882 · Cited by 1
“The potential risk of SMM (10% per year) (Kyle et al., 2007) and MGUS (1%–1.”
BackgroundRole of Conventional Cytogenetics and FISH in the Laboratory Work Up of Plasma Cell Dyscrasias
Dhabe, A., Das, S., & Parihar, M. (2023) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0043-1762920 · Cited by 1
Cancer Stem Cell Markers in Haematological Malignancies
Ramos, S. B., & Brenu, E. W. (2023) · Springer eBooks · doi:10.1007/978-981-99-3185-9_16 · Cited by 1
Nogai, A. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21207-9.00014-8 · Cited by 1
Burt, R. K., Burman, J., Barker, A., & Sharrack, B. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90242-7.00002-x · Cited by 1
Zhu, X., Feng, Z., Peng, X., Di, T., Li, Y., Bai, J. Y., Ma, T., Li, L., & Zhang, L. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114454 · Cited by 1
Immunoglobulin Quantification and Viscosity Measurement
Warren, J. S. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch7 · Cited by 1
MBBS, F. B. J. B., Clark, M. D. M., & DM, B. S. W. (2009) · Wiley eBooks · doi:10.1002/9781444309782.ch7 · Cited by 1
Haferlach, C., & Haferlach, T. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy499 · Cited by 1
Robert A. Kyle, MD: Lessons From a Legend
Rajkumar, S. V. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.030 · Cited by 1
Self-citationOn the road to molecular prognostication in SMM
Manier, S. (2019) · Leukemia · doi:10.1038/s41375-019-0627-1 · Cited by 1
Harding, T. (2018) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Levinson, S. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00141-5 · Cited by 1
Daratumumab for high-risk smoldering multiple myeloma – Are we there yet?
Lal, B. M., & Hadidi, S. A. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115391 · Cited by 1
Diagnosis and Prediction of Precursor States in Multiple Myeloma using Cell-free ChromatinPreprint
Vilk, N. O., Veinstein, V., Hermoni, N., Shaul, O., Pogrebijski, G., Harpenas, E., Lebel, E., Pick, M., Gutin, J., Gatt, M. E., et al. (2025) · medRxiv · doi:10.1101/2025.10.31.25338878 · Cited by 1
Improving the Monitoring of Multiple Myeloma Patients Using Blood Based Markers of Disease
Campbell, L. (2022) · Radar (Oxford Brookes University) · doi:10.24384/wa0k-xn78 · Cited by 3
Robert Arthur Kyle, MD: A Conversation with the Editor
Kyle, R. A., & Roberts, W. C. (2010) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2010.11928660 · Cited by 2
Self-citationMicroRNA control of drug-resistance in haematological malignancies
Screen, M. (2015) · Figshare
Multiple Myeloma: Molecular Biology, Diagnosis and Treatment
Kumar, S. K., & Rajkumar, S. V. (2011) · Wiley eBooks · doi:10.1002/9781444394016.ch20
Self-citationCaracterización de gammapatías monoclonales
Álvarez, I. H., Perera, J. C. H., Marón, L. B., Conde, C. L., Peguero, Y. E. F., & Torres, N. F. (2012) · Investigaciones Medicoquirúrgicas
Population-based studies on familiality and prognosis in patients with monoclonal gammopathies
Kristinsson, S. Y. (2009) · Figshare · Cited by 1
Nieto, W. G. (2012) · Gredos (University of Salamanca) · doi:10.14201/gredos.121199 · Cited by 1
Immunobiology and Immunotherapy of Multiple Myeloma
Dhodapkar, M. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_11
Application of targeted contrast nanoparticles for human multiple myeloma imaging
Kozłowska, D. (2012) · Dublin City University Open Access Institutional Repository (Dublin City University)
Jhaveri, A., & Muggia, F. M. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2010.182
“Patients with smoldering myeloma have a 73% chance in 15 years in progressing to multiple myeloma, and this risk is greatest in the first few years after diagnosis [4].”
BackgroundTherapie des multiplen Myeloms
Peest, D., Ganser, A., & Einsele, H. (2014) · Wiener klinisches Magazin · doi:10.1007/s00740-014-0198-8
Biologie des multiplen Myeloms
Hose, D., & Seckinger, A. (2014) · Der Onkologe · doi:10.1007/s00761-013-2568-z
Amyloidosis of the hip. Presentation of a case and a review of the literature
Cambero, R. P., Rivera, I., & Arévalo, A. S. (2011) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recote.2011.03.001
Management of Treatment Complications and Supportive Care
Buadi, F. K., & Khan, A. C. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_14
A Case Study Progression to Multiple Myeloma
Yancey, M. A., Waxman, A. J., & Landgren, O. (2010) · Clinical journal of oncology nursing · doi:10.1188/10.cjon.419-422
“Based on retrospective data from the Mayo Clinic, the average annual risk of progression from smoldering multiple myeloma to multiple myeloma is 10% for the first five years following smoldering multiple myeloma diagnosis, decreasing to 3% annually for the following five years, and becoming the same 1% annual rate of…”
BackgroundInfluentialPeptide-based immunotherapy in multiple myeloma
Podgórniak, M., Zaleska, J., & Giannopoulos, K. (2015) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2015.04.001
“[5] Kyle R, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al.”
BackgroundManagement of asymptomatic myeloma patients
Mateos, M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2015.978852
“The annual risk of progression from SMM to symptomatic MM is 10% per year for the first 5 years, 5% per year during the following 5 years and only 1% per year after 10 years [8].”
Background85-Year-Old Man With Epistaxis
Butts, M. J., Skalski, J. H., & Wittich, C. M. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0449
“Smoldering multiple myeloma, which is classified as a serum monoclonal protein of 3 g/dL or higher and/or 10% or greater bone marrow clonal plasma cells without endorgan damage (lytic lesions of bone, anemia, hypercalcemia, or renal insufficiency), portends a 10% risk per year of progression to overt multiple myeloma…”
BackgroundGammapathie monoclonale de signification indéterminée, myélome multiple et ostéoporose
Bouvard, B., Royer, M., Chappard, D., Audran, M., Hoppé, E., & Legrand, É. (2010) · Revue du Rhumatisme · doi:10.1016/j.rhum.2009.06.005 · Cited by 1
SMM: toward better predictors of progression
Bladé, J., & Rosiñol, L. (2008) · Blood · doi:10.1182/blood-2007-11-120444
THE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
Schots, R., Delforge, M., André, M. P. E., Bries, G., Caers, J., Demuynck, H., Prijck, B. D., Samblanx, H. D., Kentos, A., Meuleman, N., et al. (2010) · Acta Clinica Belgica · doi:10.1179/acb.2010.055
“Also, MM can evolve over prolonged periods of time without symptoms or end-organ damage, defi ned as asymptomatic or smoldering MM and accounting for 15% of all cases (3).”
BackgroundMultiple myeloma: the puzzle is finally completed
Leleu, X. P. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70007-9
Le myélome multiple asymptomatique: le paysage thérapeutique change
Caers, J., & Beguin, Y. P. (2014) · ORBi (University of Liège)
Martinelli, N., Carleo, P., Girelli, D., & Olivieri, O. (2011) · Circulation · doi:10.1161/circulationaha.111.061689
Jordan, W. E., Emmons, R. V. B., Vogl, D., & Morris, G. J. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.03.019 · Cited by 2
Asymptomatic (Smoldering) Myeloma: Treatment Strategy
Mateos, M., & Miguel, J. F. S. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.56
Overview of the Lymphoid Neoplasms
Podoltsev, N. A., Lacy, J., & Vose, J. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7668-0_1
Blimark, C. H. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Czekalla, H. (2010) · Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel)
Mestrado Integrado em Medicina Dissertação I Artigo de Revisão Bibliográfica
Cristina, S., Silva, V., & Salazar, A. (2012)
Ahlborn, M. (2013) · Der Onkologe · doi:10.1007/s00761-013-2591-0
Ossäre Manifestationen des multiplen Myeloms
Goldschmidt, H., Hose, D., & Hillengaß, J. (2014) · Springer eBooks · doi:10.1007/978-3-662-43471-0_15
Jiménez, J. J., Díaz, M. P., de Carvalho, N. M. B., & de Larramendi, C. H. (2015) · Journal of Applied Hematology · doi:10.4103/1658-5127.160196
Pharmacogenomic modeling of bortezomib resistance in B cell malignancies
Stessman, H. A. F. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Molecular analysis of combined mTOR/HDAC inhibition in multiple myeloma
Gamache, B. (2013) · Figshare · doi:10.57912/23868024
Assessing Risk for Progression in Smoldering Myeloma
Williams, M. E. (2007) · Journal watch · doi:10.1056/oh200706200000001
Dissemine granüloma anulare ve asemptomatik multipl myelom birlikteliği
Aktan, Ş., Akarsu, S., Avcı, C., Lebe, B., Katgı, A., & Özsan, G. H. (2013) · TURKDERM · doi:10.4274/turkderm.86094
Kyrtsonis, M. (2013) · World Journal of Hematology · doi:10.5315/wjh.v2.i2.6
Diagnosis of Smoldering Multiple Myeloma
Jacobsen, R. B., Perlman, B. B., & Gewurz, A. T. (2011)
Madan, S., & Greipp, P. R. (2011) · Wiley eBooks · doi:10.1002/9781444345254.ch22
Early treatment for high-risk smouldering myeloma: has the time come?
Ludwig, H. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30151-6
Multiple Myeloma and Plasma Cell Dyscrasias
Raje, N. S., Anderson, K. C., Dorfman, D. M., & Skarin, A. T. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05905-3.00017-0
Fonseca, R., & Valdez, R. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511760273.013
Self-citationGorczyca, W., & Emmons, F. N. (2008) · CRC Press eBooks · doi:10.3109/9781439806487-14
R-ISS and NLR-ISS can Predict Time to Treatment in Smoldering Myeloma
Romano, A., Consoli, M. L., & Auteri, G. (2016) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000292
“Despite the effect of such changes on the estimates is considered minimal for the low proportion of patients upstaged from SMM to MM [4], we used in our analysis the new, most stringent definition of sMM.”
BackgroundMethodInfluentialSmoldering (asymptomatic) Multiple Myeloma: Cure-versus-control Debate
Hamed, N. A. M. (2015) · doi:10.24947/baojcrt/1/2/00110
“After 10 years of follow up, risk of progression from SMM to MM is similar to that of MGUS (∼1% risk per year on average) [8].”
MethodManagement of smoldering myeloma: Recommendations of the Spanish Myeloma Group
Mateos, M., Bladé, J., Lahuerta, J. J., & Miguel, J. F. S. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.05.003
Rôle de la molécule APRIL dans le développement des hémopathies malignes B
Manfroi, B. (2017) · theses.fr (ABES) · doi:10.70675/da3cf251z26e8z4c94z8c42z22a8bda0cec3
“De manière similaire au MGUS, la transformation en MM peut passer au préalable par le stade de SMM avec cette fois un risque accru de transformation en MM avec 10% par an (Kyle et al., 2007).”
BackgroundInfluence of microRNA on Resistance to Proteasome Inhibitors in Multiple Myeloma
Degelman, E. (2012) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/18414
Integration neuer Substanzen in bestehende Therapieschemata
Schmale (2018) · Onkologische Welt · doi:10.1055/s-0038-1637720
Monoclonal Gammopathy of Undetermined Significance
Hultcrantz, M. L., & Landgren, O. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_25
Chen, A., Hoppe, R. T., & Coutre, S. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5897-7.00065-2
ElGhammaz, A. (2016) · Egyptian Journal of Hematology and Bone Marrow Transplantation · doi:10.21608/ejhbmt.2016.19697
“2) The size of the M spike and the degree of plasmacytosis were also consistent risk factors [10].”
BackgroundTherapeutic Targets and Signaling Pathways for Diagnosis of Myeloma
Ahmed, Z. A., Nasir, A., Shaikh, M. S., Moatter, T., & Rasheed, A. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81751
MULTIPLE MYELOMA- ANALYSIS OF DIAGNOSTIC CRITERIA AND PROGNOSTIC FACTORS
Prema, K. R., K, P. K., & Jose, M. (2018) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2018/700
Miguel, J. F. S., & Bladé, J. (2010) · Wiley eBooks · doi:10.1002/9781444323160.ch31 · Cited by 1
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.